Rigel Pharmaceuticals, Inc.
RIGL
$46.38
$1.974.43%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 69.46M | 101.69M | 53.33M | 57.60M | 55.31M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 69.46M | 101.69M | 53.33M | 57.60M | 55.31M |
| Cost of Revenue | 12.11M | 11.33M | 12.85M | 11.42M | 14.21M |
| Gross Profit | 57.36M | 90.36M | 40.49M | 46.18M | 41.10M |
| SG&A Expenses | 28.94M | 29.26M | 27.72M | 29.52M | 27.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.04M | 40.58M | 40.56M | 40.94M | 41.25M |
| Operating Income | 28.42M | 61.10M | 12.77M | 16.66M | 14.06M |
| Income Before Tax | 27.62M | 59.98M | 11.51M | 15.22M | 12.42M |
| Income Tax Expenses | -280.00K | 369.00K | 65.00K | 881.00K | -- |
| Earnings from Continuing Operations | 27.90M | 59.61M | 11.45M | 14.34M | 12.42M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.90M | 59.61M | 11.45M | 14.34M | 12.42M |
| EBIT | 28.42M | 61.10M | 12.77M | 16.66M | 14.06M |
| EBITDA | 29.02M | 61.71M | 13.38M | 17.26M | 14.67M |
| EPS Basic | 1.55 | 3.33 | 0.64 | 0.81 | 0.71 |
| Normalized Basic EPS | 0.96 | 2.10 | 0.40 | 0.54 | 0.44 |
| EPS Diluted | 1.46 | 3.28 | 0.63 | 0.80 | 0.70 |
| Normalized Diluted EPS | 0.90 | 2.06 | 0.40 | 0.53 | 0.44 |
| Average Basic Shares Outstanding | 18.04M | 17.89M | 17.81M | 17.65M | 17.60M |
| Average Diluted Shares Outstanding | 19.16M | 18.16M | 18.17M | 17.99M | 17.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |